MNKD — MANNKIND CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 899460 ·
Last close
$4.07
Market Cap
$1.31B
52W High
$6.51
52W Low
$2.23
ADV30
3,648,405
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 101,870,000 | 78,358,000 | -2,574,000 | -23,224,000 | 722,616,000 | 41,276,000 | 759,882,000 |
| Jun 2026 | 109,375,000 | 79,835,000 | -835,000 | -19,032,000 | 732,304,000 | 52,929,000 | 799,501,000 |
| Mar 2026 | 90,171,000 | 72,698,000 | -2,985,000 | -16,619,000 | 744,403,000 | 52,834,000 | 803,598,000 |
| Dec 2025 | 111,955,000 | 82,282,000 | -7,690,000 | -15,948,000 | 792,182,000 | 74,882,000 | 843,204,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,054,000
Investing CF
$-280,387,000
Financing CF
$284,372,000
CapEx
$-10,081,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,231,607,000
Inventory
$44,419,000
Receivables
$43,207,000
ST Investments
$58,201,000
EBIT TTM
$-506,000
Pretax Income TTM
$-48,654,000
Interest Exp TTM
$48,148,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$413,371,008
EBITDA
$-1,942,000
Free Cash Flow
$-19,861,250
Enterprise Value
$1,735,910,400
Total Cash
$96,609,000
Total Debt
$578,123,008
Shares Out
321,640,118
Trailing EPS
$-0.24
Book Value
$-0.12
ROE
—
ROA
-1.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 348,966,000 | 46,550,000 | 5,863,000 | 792,182,000 | 843,204,000 | -51,022,000 | 18,255,000 |
| Dec 2024 | 285,504,000 | 68,680,000 | 27,588,000 | 393,843,000 | 472,659,000 | -78,816,000 | 42,511,000 |
| Dec 2023 | 198,962,000 | 10,594,000 | -11,938,000 | 475,198,000 | 721,366,000 | -246,168,000 | 34,094,000 |
| Dec 2022 | 99,770,000 | -68,921,000 | -87,400,000 | 295,282,000 | 545,820,000 | -250,538,000 | -80,679,000 |
TTM Snapshot
Revenues TTM
$393,630,000
NetIncome TTM
$-43,614,000
OpCashFlow TTM
—
Assets (Latest)
$732,304,000
Forward EPS
$0.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | $1.30B | $40.30 | — |
| GPCR | Structure Therapeutics Inc. | $1.30B | $18.17 | — |
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
| MLYS | Mineralys Therapeutics, Inc. | $1.28B | $14.48 | — |
News headlines (Yahoo Finance, 1h cache)
MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
2026-11-18 12:13 · Yahoo
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
2026-11-18 05:12 · Yahoo
MannKind to Participate in Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
MannKind (MNKD) Q3 2026 Earnings Call Transcript
2026-11-06 14:44 · Yahoo
MannKind Corporation Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ...
2026-11-06 11:19 · Yahoo
Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results?
2026-11-06 10:13 · Yahoo
MannKind Q3 Earnings Call Highlights
2026-11-06 07:14 · Yahoo
Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
2026-11-05 22:30 · Yahoo
MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 21:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.